Glaukos Corp. GKOS 深 沪
等待开盘 08-16 09:30:00 美东时间
89.86
-1.220
-1.34%
华盛通- 最 高92.22
- 今 开91.35
- 成交量 90.72万股
- 最 低 89.13
- 昨 收 91.08
- 总市值 51.53亿
- 52周最高 163.71
- 市盈率 静 --
- 换手率 1.58%
- 52周最低 77.1018
- 委 比 97.02%
- 总股本 5735.00万
- 历史最高 163.71
- 量 比 1.04
- 振 幅 3.39%
- 历史最低 14.25
- 每 手 1
- 风险率 21.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Glaukos shares are trading lower. The company reported Q2 financial results.
Glaukos shares are trading lower. The company reported Q2 financial results.
07-31 23:46
UBS Maintains Buy on Glaukos, Raises Price Target to $134
UBS analyst Danielle Antalffy maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $125 to $134.
07-31 21:04
Glaukos Raises FY2025 Sales Guidance from $475.00M-$485.00M to $480.00M-$486.00M vs $480.78M Est
Glaukos (NYSE:GKOS) raises FY2025 sales outlook from $475.00 million-$485.00 million to $480.00 million-$486.00 million vs $480.78 million estimate.
07-31 04:13
Glaukos Q2 Adj. EPS $(0.24) Beats $(0.26) Estimate, Sales $124.12M Beat $115.51M Estimate
Glaukos (NYSE:GKOS) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.34 percent. This is a 53.85 percent increase over losses of $(0.52) per share from the same
07-31 04:13
Earnings Outlook For Integer Holdings
Integer Holdings (NYSE:ITGR) is gearing up to announce its quarterly earnings o...
04-24 01:01
美股大行评级 | 潜在涨幅89.34%！Loop Capital上调Warby Parker目标价至27美元，评级升至"买入"
每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。
04-18 08:48
美股大行评级 | 潜在涨幅195.08%！Absci获Keybanc升目标价至9美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1119548656129204224.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Keybanc：维持Absci(ABSI)"超配"评级，目标价从5美元升至9美元</p> <p>• Keybanc：维持AbCellera Biologics(ABCL)"超配"评级，目标价从4美元升至5美元</p> <
04-17 08:46
Forecasting The Future: 7 Analyst Projections For Glaukos
In the preceding three months, 7 analysts have released ratings for Glaukos (NY...
04-17 06:01
美股大行评级 | 潜在涨幅684.71%！Verve Therapeutics获Canaccord Genuity升目标价至39美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1119185980869894144.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Canaccord Genuity：维持Verve Therapeutics(VERV)"买入"评级，目标价从32美元升至39美元</p> <p>• HC Wainwright & Co.：维持Verve Ther
04-16 09:45
美股大行评级 | 潜在涨幅223.78%！内克塔治疗获杰富瑞升目标价至2美元，上调至"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1117736711687032832.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 杰富瑞：上调内克塔治疗(NKTR)评级至"买入"，目标价从1美元升至2美元</p> <p>• Roth MKM：维持Lovesac Co.(LOVE)"买入"评级，目标价从22美元升至28美元</p> <p>• Macq
04-14 07:05
